×
About 3,528 results

ALLMedicine™ Tuberous Sclerosis Center

Research & Reviews  1,323 results

A Case Report of Cystic Fibrosis Plus Tuberous Sclerosis: A Cautionary Tale Regarding L...
https://doi.org/10.1016/j.transproceed.2021.08.022
Transplantation Proceedings; Laghi FA, Saad M et. al.

Sep 23rd, 2021 - Cystic fibrosis (CF) and tuberous sclerosis complex (TSC) are 2 rare genetic diseases that often affect the lungs. Pulmonary compromise in TSC or CF can be severe enough to require lung transplantation. In rare instances patients with CF undergo p...

Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells.
https://doi.org/10.1073/pnas.2101268118
Proceedings of the National Academy of Sciences of the Un... Wang J, Filippakis H et. al.

Sep 22nd, 2021 - Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are caused by aberrant mechanistic Target of Rapamycin Complex 1 (mTORC1) activation due to loss of either TSC1 or TSC2 Cytokine profiling of TSC2-deficient LAM patient-derived ce...

Tuberous Sclerosis: Current Update.
https://doi.org/10.1148/rg.2021210103
Radiographics : a Review Publication of the Radiological ... Wang MX, Segaran N et. al.

Sep 18th, 2021 - Tuberous sclerosis complex (TSC) is a relatively rare autosomal dominant neurocutaneous disorder secondary to mutations in the TSC1 or TSC2 tumor suppressor genes. Although manifestation of the classic triad of seizures, intellectual disability, a...

see more →

Guidelines  2 results

Treatment of Infantile Spasms: Report of the Interdisciplinary Guideline Committee Coor...
https://doi.org/10.1055/s-0036-1572411
Neuropediatrics Tibussek D, Klepper J et. al.

Feb 26th, 2016 - Objectives This report aims to define treatment goals, to summarize the evidence level (EL) of different treatment options for infantile spasms (IS), both in terms of efficacy and adverse effect, and to give recommendations for the management of I...

The ERS guidelines for LAM: trying a rationale approach to a rare disease.
https://doi.org/10.1016/j.rmed.2010.03.015
Respiratory Medicine; Johnson SR

May 11th, 2010 - Lymphangioleiomyomatosis (LAM) is a rare lung disease which predominantly affects young women. LAM is associated with much morbidity and can lead to respiratory failure and death unless lung transplantation is performed. There are no randomised tr...

see more →

Drugs  8 results see all →

News  78 results

Cannabidiol Cleared for Tuberous Sclerosis Complex in Europe
https://www.medscape.com/viewarticle/949596

Apr 20th, 2021 - The European Commission (EC) has approved cannabidiol (Epidyolex) oral solution as adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older. It's the third indication for the drug in Euro...

Cannabinoids 'Worth a Try' for Agitation in Alzheimer's
https://www.medscape.com/viewarticle/945163

Feb 2nd, 2021 - Tetrahydrocannabinol (THC), the psychoactive agent in cannabinoids, may provide an alternative to off-label use of antipsychotics and other medications to manage agitation in patients with Alzheimer's disease (AD), a new clinical review suggests. ...

Preventive Treatment Delays First Seizure Onset in Tuberous Sclerosis Complex
https://www.medscape.com/viewarticle/939609

Oct 22nd, 2020 - In patients with tuberous sclerosis complex (TSC), preventive treatment with vigabatrin is safe and changes the natural history of seizures, according to research presented at the 2020 CNS-ICNA Conjoint Meeting, held virtually this year. This trea...

FDA Approves Cannabidiol for Tuberous Sclerosis Complex
https://www.medscape.com/viewarticle/935067

Aug 3rd, 2020 - The cannabidiol (CBD) oral solution Epidiolex has been approved by the US Food and Drug Administration (FDA) for the new indication of treatment of seizures associated with tuberous sclerosis complex in patients 1 year of age and older. The drug w...

FDA Approves Cannabidiol for Tuberous Sclerosis Complex
https://www.staging.medscape.com/viewarticle/935067

Aug 3rd, 2020 - The cannabidiol (CBD) oral solution Epidiolex has been approved by the US Food and Drug Administration (FDA) for the new indication of treatment of seizures associated with tuberous sclerosis complex in patients 1 year of age and older. The drug w...

see more →